1309952-03-1
Chemical Structure
BI-1388
- CAS No.: 1309952-03-1
- Formula:C41H53N7O9S
- Molecular Weight:819.97
IUPAC Name: (2R,6S,13aS,14aR,16aS,Z)-2-((2-isopropoxy-7-methoxy-8-methylquinolin-4-yl)oxy)-6-(1-methyl-1H-pyrazole-3-carboxamido)-N-((1-methylcyclopropyl)sulfonyl)-5,16-dioxo-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide
InChIKey: WSEPMWSQALXHKW-WDBXFCNMSA-N
SMILES: O=C([C@]([C@]1([H])/C=C\CCCCC[C@@H]2NC(C3=NN(C)C=C3)=O)(C1)NC([C@@](C[C@@H](OC4=CC(OC(C)C)=NC5=C(C)C(OC)=CC=C45)C6)([H])N6C2=O)=O)NS(=O)(C7(C)CC7)=O
Biological Activity: BI-1388 is a macrocyclic acylsulfonamide-based HCV NS3-4A protease inhibitor. BI-1388 inhibits clinically relevant drug-resistant mutant strains (KRASD168V gt 1b and KRASR155K gt 1a) and exhibits high liver distribution. BI-1388 is applicable for the research of HCV infection[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
BI-1388 | BI-1388 is a macrocyclic acylsulfonamide-based HCV NS3-4A protease inhibitor. BI-1388 inhibits clinically relevant drug-resistant mutant strains (KRASD168V gt 1b and KRASR155K gt 1a) and exhibits high liver distribution. BI-1388 is applicable for the research of HCV infection. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
